Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)

NCT00319631 | Withdrawn DMC

• 1 other identifier: VEGF in ARDS
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Understanding the role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.

Conditions

Respiratory Distress Syndrome, Adult

Keywords

Respiratory Distress Syndrome, Adult

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects for the study will be drawn from endotracheally intubated inpatients of The New York Presbyterian Hospital-Weill Cornell Medical Center diagnosed with ALI or ARDS or who are at risk for developing ARDS.

You may qualify if:

• Patients that meet the American-European Consensus Conference criteria for ARDS \[(1) Widespread pulmonary infiltrates; (2) Pulmonary capillary wedge pressure 18 mmHg; (3) PaOz/FiO; ratio 200; (4) compatible history\], or acute lung injury \[same as ARDS, but PaOz/FiOz ratio 300\], or are at increased risk for developing acute lung injury because of sepsis, pancreatitis, trauma, acid aspiration, radiation or chemotherapy-induced lung toxicity, and near drowning. Pulmonary edema is divided into two broad categories: hydrostatic or cardiogenic and increased-permeability or noncardiogenic edema12. Since ARDS is noncardiogenic in origin, patients with pulmonary edema due to congestive heart failure will serve as a control group.
• Inpatients that are endotracheally intubated.
• Patients that are able to provide informed consent or informed consent is granted by a family member or legal health care proxy.
• Males or females that are 18 years or older.

You may not qualify if:

• \- Individuals who are too hypoxemic for bronchoscopy to be performed safely. Patients requiring V\\0z \> 0.7 and/or PEEP 15 will be excluded.
• \. If the patient will be unable to tolerate bronchoscopy because of severe
• acidosis, tension pneumothorax, active bronchospasm, hemodynamically significant cardiac arrhythmia, or intractable shock as defined as the inability to maintain a mean arterial pressure 60 mmHg or severe uncorrectable bleeding diathesis (tendency) or as otherwise determined by the pulmonary physician.
• \. Females who are pregnant will not be accepted into the study. 4. Patients with recent (48 hours) acute myocardial infraction will not be accepted into the study.
• \. Patients with a history of adverse reactions to lidocaine will be not be accepted into the study. 6. Patients who lack capacity to give informed consent due to acute panic attack, "intensive care unit" psychosis or other psychologic dysfunction.

Sponsors & Collaborators

• Weill Medical College of Cornell University: lead

Study Sites (1)

Weill Medical College of Cornell University

New York, New York, 10021, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Respiration Disorders

Study Officials

• Robert J. Kaner, M.D.

  Weill Medical College of Cornell University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2006
• First Posted: April 27, 2006
• Study Start: January 1, 2006
• Primary Completion: January 1, 2017
• Study Completion: January 1, 2017
• Last Updated: January 30, 2017

Record last verified: 2017-01

Locations

US (1)